sb 203580 has been researched along with 2-[(3-iodophenyl)methylthio]-5-pyridin-4-yl-1,3,4-oxadiazole in 3 studies
| Studies (sb 203580) | Trials (sb 203580) | Recent Studies (post-2010) (sb 203580) | Studies (2-[(3-iodophenyl)methylthio]-5-pyridin-4-yl-1,3,4-oxadiazole) | Trials (2-[(3-iodophenyl)methylthio]-5-pyridin-4-yl-1,3,4-oxadiazole) | Recent Studies (post-2010) (2-[(3-iodophenyl)methylthio]-5-pyridin-4-yl-1,3,4-oxadiazole) |
|---|---|---|---|---|---|
| 3,489 | 4 | 1,137 | 7 | 0 | 3 |
| Protein | Taxonomy | sb 203580 (IC50) | 2-[(3-iodophenyl)methylthio]-5-pyridin-4-yl-1,3,4-oxadiazole (IC50) |
|---|---|---|---|
| G2/mitotic-specific cyclin-B2 | Homo sapiens (human) | 10 | |
| Cyclin-dependent kinase 1 | Homo sapiens (human) | 10 | |
| G2/mitotic-specific cyclin-B1 | Homo sapiens (human) | 10 | |
| Glycogen synthase kinase-3 alpha | Homo sapiens (human) | 4.195 | |
| Glycogen synthase kinase-3 beta | Homo sapiens (human) | 1.725 | |
| G2/mitotic-specific cyclin-B3 | Homo sapiens (human) | 10 |
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 0 (0.00) | 18.2507 |
| 2000's | 2 (66.67) | 29.6817 |
| 2010's | 1 (33.33) | 24.3611 |
| 2020's | 0 (0.00) | 2.80 |
| Authors | Studies |
|---|---|
| Bilter, GK; Dias, J; Huang, Z; Keon, BH; Lamerdin, J; MacDonald, ML; Michnick, SW; Minami, T; Owens, S; Shang, Z; Westwick, JK; Yu, H | 1 |
| Bullock, AN; Fedorov, O; Knapp, S; Marsden, B; Müller, S; Pogacic, V; Rellos, P; Schwaller, J; Sundström, M | 1 |
| Augustin, M; Davies, SP; Gao, Y; Harvey, KJ; Kovelman, R; Patel, UA; Woodward, A | 1 |
3 other study(ies) available for sb 203580 and 2-[(3-iodophenyl)methylthio]-5-pyridin-4-yl-1,3,4-oxadiazole
| Article | Year |
|---|---|
Identifying off-target effects and hidden phenotypes of drugs in human cells.
Topics: Bacterial Proteins; Cell Line; Cell Proliferation; Cluster Analysis; Drug Design; Drug Evaluation, Preclinical; Genetics; Humans; Luminescent Proteins; Molecular Structure; Phenotype; Recombinant Fusion Proteins; Signal Transduction; Structure-Activity Relationship | 2006 |
A systematic interaction map of validated kinase inhibitors with Ser/Thr kinases.
Topics: Amino Acid Sequence; Binding Sites; Clinical Trials as Topic; Drug Evaluation, Preclinical; Enzyme Stability; Humans; Molecular Sequence Data; Phylogeny; Protein Array Analysis; Protein Conformation; Protein Kinase Inhibitors; Protein Serine-Threonine Kinases | 2007 |
A broad activity screen in support of a chemogenomic map for kinase signalling research and drug discovery.
Topics: Aurora Kinases; Cluster Analysis; Drug Design; Drug Discovery; Drug Evaluation, Preclinical; ErbB Receptors; Humans; Intracellular Signaling Peptides and Proteins; MAP Kinase Kinase 4; p38 Mitogen-Activated Protein Kinases; Protein Kinase Inhibitors; Protein Kinases; Protein Serine-Threonine Kinases; Protein-Tyrosine Kinases; Receptors, Vascular Endothelial Growth Factor; Recombinant Proteins; Reproducibility of Results; Signal Transduction; Small Molecule Libraries; Structure-Activity Relationship; Syk Kinase | 2013 |